SLIRP Maintains Mitochondrial mRNA Stability and OXPHOS in Colorectal Cancer

Colorectal cancer (CRC) commonly exhibits increased vascularity and, in many cases, augmented oxidative phosphorylation (OXPHOS) activity.

Prior literature has proposed OXPHOS as a metabolic vulnerability amenable to therapeutic exploitation.

SLIRP is a known RNA‑binding protein implicated in post‑transcriptional control of mitochondrial gene expression, but its role in CRC had not been defined prior to the study summarized here.

The investigators sought to define SLIRP’s localisation, expression pattern, and functional role in CRC, and to elucidate molecular mechanisms by which SLIRP might influence mitochondrial gene expression and cellular energetics.

They combined analysis of clinical specimens and public datasets with cellular experiments addressing growth, apoptosis, metabolism, RNA binding, and mRNA stability.

• Clinical material and publicly available databases were interrogated to assess SLIRP protein localisation within cells and differential expression between CRC tissues and adjacent non‑tumour tissue, and to examine associations with patient survival.
• In vitro functional studies employed CRC cell lines with SLIRP depletion to evaluate effects on cellular ATP levels, proliferation, and apoptosis.
• Molecular mechanisms were addressed using RNA immunoprecipitation to identify SLIRP‑RNA interactions and mRNA stability assays to measure post‑transcriptional effects on mitochondrial‑encoded transcripts.

• Exposure: SLIRP expression level and cellular localisation.
• Outcomes: Changes in OXPHOS activity inferred from cellular ATP status, tumor cell growth metrics, apoptotic indices, binding of SLIRP to mitochondrial transcripts, and stability of those transcripts.

Higher SLIRP expression was associated with poorer patient survival in the datasets examined.

Complementary mRNA stability assays showed that SLIRP contributes to the maintenance of those mitochondrial transcripts’ stability, consistent with a role as a post‑transcriptional regulator of mitochondrial gene expression.

• Expression and clinical association: SLIRP expression was elevated in CRC tissue samples relative to matched adjacent normal tissue.
• Functional consequences of depletion: Knockdown of SLIRP in CRC cell lines produced a pronounced reduction in cellular ATP (described as an “ATP crisis”), concomitant with suppressed tumour cell growth and increased apoptosis.
• Mechanistic insights: RNA immunoprecipitation experiments indicated that SLIRP binds broadly to mitochondrial‑encoded mRNAs.
• Interpretation: The authors propose that SLIRP supports OXPHOS function in CRC by stabilising mitochondrial transcripts, thereby preserving mitochondrial‑encoded components essential for respiratory chain activity.

The report situates its findings among broader bodies of work on metabolic reprogramming in CRC and on mitochondrial gene regulation in cancer.

The study cites prior investigations exploring OXPHOS as a therapeutic target, molecular regulators of mitochondrial transcription and translation, and emerging strategies that exploit mitochondrial vulnerabilities in malignancy.

• The source does not report details on sample sizes, cohort characteristics, or statistical metrics underpinning the survival association and expression analyses; these elements were not provided in the summary.
• Translational implications are framed as potential prognostic and therapeutic relevance, but the source does not provide clinical trial data or in vivo efficacy evidence within this report.
• The summary does not describe whether the experiments addressed isoform specificity, off‑target effects of knockdown, or rescue experiments to confirm causality; these methodological specifics were not reported in the provided content.

• The findings identify SLIRP as a candidate regulator of mitochondrial transcript stability in CRC and suggest that its expression correlates with adverse prognosis; this raises questions about whether SLIRP status could serve as a biomarker or guide metabolic strategies.
• Unresolved issues include corroboration of these cellular results in animal models or clinical cohorts with robust outcome data, mechanistic dissection of how SLIRP engages specific mitochondrial transcripts and protein complexes, and assessment of potential safety or specificity considerations for strategies targeting SLIRP.

The authors indicate that all data generated or analysed in the study are provided within the published article and its supplementary information files.